La fisiopatología del consumo de grasas saturadas y aceite de coco: una revisión exhaustiva de la lipidología, el riesgo cardiometabólico y la redundancia fisiológica

La comprensión clínica de las grasas dietéticas ha sido objeto de un escrutinio significativo durante el último siglo, pasando de un mensaje generalizado de “bajo en grasa” a un paradigma sofisticado y centrado en la calidad. Dentro de este panorama, aceite de coco ha surgido como un punto focal de intenso debate, a menudo caracterizado por una marcada división entre la comercialización de los “superalimentos” y la lipidología clínica rigurosa. Los defensores del aceite de coco suelen argumentar que su perfil único de ácidos grasos confiere ventajas metabólicas, en particular en lo que respecta a pérdida de peso, la salud tiroidea y la resistencia antimicrobiana, al tiempo que desafían el vínculo establecido entre los ácidos grasos saturados y la ateroesclerosis enfermedad cardiovascular. Sin embargo, un análisis profundo de las investigaciones revisadas por pares, los estudios genéticos y ensayos controlados aleatorizados ofrece una perspectiva más matizada y de cautela. Este informe examina la composición bioquímica del aceite de coco y evalúa la causalidad de la baja densidad lipoproteínas en la patología cardiovascular, deconstruye los mitos endocrinos y metabólicos comunes, y aborda la redundancia fisiológica de la dieta grasa saturada a través de la lente de lipogénesis de novo.

Análisis bioquímico y la idea errónea sobre los MCT

La justificación principal de los supuestos beneficios para la salud del aceite de coco suele centrarse en su clasificación como fuente de triglicéridos de cadena media (TCM). Para evaluar esta afirmación, es necesario analizar las longitudes específicas de las cadenas de carbono de los ácidos grasos que componen el aceite. El aceite de coco está compuesto predominantemente por grasas saturadas (que, según los datos habituales, representan entre ~84 y 92% del total de ácidos grasos, dependiendo del procesamiento y del método analítico) [1-3]. El ácido graso predominante es ácido láurico (C12:0), lo que representa aproximadamente entre 45% y 53% del total de ácidos grasos en la mayoría de los análisis composicionales [1-3].

Existe una distinción crítica entre los ácidos grasos de cadena media verdaderos, como ácido caprílico (C8:0) y el ácido cáprico (C10:0), y el ácido láurico (C12:0), que es un ácido graso de cadena media “limítrofe”. En nutrición clínica, los triglicéridos de cadena media (TCM) suelen definirse operativamente por su absorción y oxidación relativamente rápidas en comparación con los de cadena larga triglicéridos, y por una mayor propensión —especialmente para el C8:0 y el C10:0— a ingresar a la circulación portal y experimentar beta-oxidación hepática [4]. Esta vía metabólica es una razón por la cual se han investigado los preparados concentrados de TCM en cuanto a sus efectos sobre el gasto energético y saciedad [4Sin embargo, los estudios metabólicos en humanos demuestran que los ácidos grasos de cadena media aún pueden incorporarse en quilomicrón triglicéridos, y la magnitud del transporte linfático aumenta con la longitud de la cadena (comportándose el C12:0 más como un ácido graso de cadena larga que el C8:0/C10:0) [5]. En consecuencia, los efectos mecanísticos informados para los aceites MCT purificados enriquecidos casi exclusivamente en C8:0 y C10:0 no deben extrapolarse automáticamente al aceite de coco entero, el cual está dominado por C12:0 y también contiene cantidades sustanciales ácido mirístico (C14:0) y ácido palmítico (C16:0) [1-3].

Composición de ácidos grasos del aceite de coco frente a otras grasas

La siguiente tabla detalla los perfiles de ácidos grasos de las grasas dietéticas comunes, destacando la concentración única de C12:0 y C14:0 en el aceite de coco en comparación con las grasas animales y los aceites vegetales (los valores son rangos aproximados extraídos de análisis de composición de alimentos y referencias de química lipídica) [1-3].

Ácido graso (cadena de carbono)	Nombre químico	Aceite de coco (%)	Grasa láctea (%)	Manteca de cerdo (%)	Aceite de oliva (%)
Butírico (C4:0)	Ácido butírico	0	3–4	0	0
Caproico (C6:0)	Ácido caproico	<1	2	0	0
Caprílico (C8:0)	Ácido caprílico	7–9	1–2	0	0
Cáprico (C10:0)	Ácido cáprico	6–7	2–3	0	0
Láurico (C12:0)	Ácido láurico	45–53	2–3	<1	0
Mirístico (C14:0)	Ácido mirístico	16–21	8–11	1–2	0
Palmítico (C16:0)	Ácido palmítico	7–10	22–26	25–28	10–14
Estearico (C18:0)	Ácido esteárico	2–4	12–15	12–14	2–4
Oleico (C18:1)	Ácido oleico	5–8	25–30	40–45	65–80
Linoleico (C18:2)	Ácido linoleico	1–3	2–3	8–10	5–15

Figura 1. Representación esquemática en barras apiladas de la composición aproximada de ácidos grasos (se muestran los valores de los puntos medios) para grasas seleccionadas; este gráfico es ilustrativo y tiene como fin hacer que los rangos tabulados sean visualmente comparables, no sustituir los análisis composicionales primarios.

Como se muestra, la concentración de AGCM de cadena más corta (C8:0 y C10:0) en el aceite de coco es moderada en relación con el C12:0 [1-3Los altos niveles de ácidos láurico y mirístico son particularmente relevantes para la lipidología clínica, ya que estos ácidos grasos saturados se cuentan entre los moduladores dietéticos más potentes en la elevación del colesterol LDL cuando se intercambian de forma isocalórica por grasas cis-insaturadas6,9].

El rol causal de las lipoproteínas de baja densidad en la aterosclerosis

Una de las afirmaciones más persistentes en la prensa popular es que el vínculo entre las grasas saturadas y las enfermedades cardíacas se basa únicamente en datos epidemiológicos defectuosos. Esta afirmación ignora décadas de avances en la investigación genética, ensayos controlados aleatorizados (ECA) y ciencia básica. El europeo Ateroesclerosis El panel de consenso de la Sociedad (EAS) ha resumido la evidencia de que las lipoproteínas de baja densidad (LDL) no son meramente marcadores de riesgo, sino agentes causales en el desarrollo de la enfermedad cardiovascular aterosclerótica (ASCVD) [10].

Evidencia de estudios genéticos y de aleatorización mendeliana

Aleatorización mendeliana y otros enfoques genéticos proporcionan herramientas para la inferencia causal al aprovechar las variantes genéticas que influyen en los niveles de c-LDL desde el nacimiento. A través de múltiples mecanismos genéticos que reducen el c-LDL, la exposición de por vida a un c-LDL más bajo se asocia consistentemente con un riesgo de ECVA proporcionalmente menor, lo que respalda un marco de “carga acumulativa de LDL” para placa iniciación y progresión10].

Resultados de ensayos controlados aleatorizados

Ensayos aleatorizados de terapias para reducir el C-LDL (por ejemplo, estatinas, ezetimiba, inhibidores de la PCSK9) demuestran reducciones dependientes de la dosis en los eventos vasculares mayores con la reducción del C-LDL. Colesterol La colaboración de los ensayistas de tratamiento (CTT) informó que cada reducción de ~1.0 mmol/L en el C-LDL reduce la tasa anual de eventos vasculares mayores en poco más de una quinta parte, sin evidencia de un umbral inferior dentro de los rangos estudiados [11]. Los ensayos de alimentación dietética y la evidencia combinada también respaldan que reemplazar las grasas saturadas con grasas poliinsaturadas reduce el c-LDL y disminuye los eventos coronarios, mientras que el reemplazo por refinados carbohidrato no mejora de manera confiable los resultados9].

Se ha demostrado en metaanálisis de ensayos controlados aleatorizados que el consumo de aceite de coco aumenta el c-LDL en comparación con los aceites vegetales insaturados no tropicales, al tiempo que a menudo también aumenta el c-HDL [6,7]. Aunque el aumento del c-LDL puede ser menor que el observado con la mantequilla en algunas comparaciones, es consistentemente menos favorable que la sustitución por aceites cis-insaturados como los aceites de oliva, cártamo, girasol, soya y canola [6-8].

Comparación del perfil lipídico: aceite de coco frente a otras fuentes de grasas

Parámetro lipídico	Aceite de coco vs. mantequilla	Coconut oil vs. unsaturated oils
Total cholesterol	Lower or neutral in some comparisons [6-8]	Higher [6,7]
LDL-cholesterol	Lower or neutral in some comparisons [6-8]	Higher [6,7]
HDL-cholesterol	Higher [6,7]	Higher [6,7]
LDL:HDL ratio	Lower/neutral in some comparisons [6-8]	Higher/less favorable [6,7]

Figure 2. Schematic bar chart reflecting the *directionality* of lipid changes reported in randomized comparisons; this figure is not intended to represent absolute unit changes and should be interpreted alongside the cited meta-analyses and trials.

The clinical significance of these changes must be interpreted through the lens of causality. Because LDL-C reflects exposure to atherogenic apoB-containing lipoproteins and LDL is causal in atherosclerosis, LDL-C increases associated with coconut oil consumption plausibly increase absolute ASCVD risk, regardless of simultaneous HDL-C increases [9-11].

El ApoB Paradigm and the “Large Fluffy LDL” Myth
A common defense of coconut oil is the claim that it primarily raises “large, fluffy” LDL particles (Pattern A), which are allegedly not atherogenic, rather than “small, dense” LDL particles (Pattern B). This narrative is increasingly viewed as an oversimplification. The atherogenicity of apoB-containing lipoproteins is primarily driven by the number of particles capable of entering and being retained within the arterial intima, not by a reassuring label of “large” or “small” particles [12,13].

Each partícula aterogénica—whether VLDL, IDL, or LDL—contains exactly one molecule of apolipoproteína B (apoB). Therefore, apoB concentration is a direct measure of the total number of atherogenic particles [12,13]. Discordance analyses have shown that when LDL-C and apoB provide different risk estimates, ASCVD risk more closely tracks apoB [12,13]. A recent scientific review of discordance evidence concluded that apoB is a more accurate marker of cardiovascular risk than LDL-C or non–HDL-C when these measures disagree [12].

Coconut oil has been reported to raise LDL-C in clinical trials and meta-analyses; when LDL-C rises, apoB often rises in parallel, particularly in patterns characterized by increased apoB particle exposure over time [6,12,13]. Accordingly, focusing on particle “size” without accounting for apoB particle number risks misclassifying lipid-mediated ASCVD risk.

The HDL Paradox and Functional Limitations

Another central pillar of the “healthy coconut oil” argument is its ability to raise HDL-C levels. While observational studies historically showed an inverse relationship between HDL-C and cardiovascular events, pharmacological attempts to reduce ASCVD by raising HDL-C have not produced consistent benefit. In the dal-OUTCOMES trial, dalcetrapib increased HDL-C but did not reduce cardiovascular events after acute coronary syndrome [14]. In the ACCELERATE trial, evacetrapib substantially raised HDL-C and lowered LDL-C, yet did not reduce cardiovascular outcomes in high-risk patients [15]. In AIM-HIGH, adding extended-release niacina to intensive statin therapy increased HDL-C but did not reduce cardiovascular events [16]. Similarly, in HPS2-THRIVE, niacin/laropiprant added to statin-based therapy did not significantly reduce major vascular events and increased adverse events [17].

Mendelian randomization also challenges the assumption that higher HDL-C is causally protective. In a landmark study, genetic mechanisms that raise HDL-C did not uniformly lower infarto de miocardio risk, undermining the view that simply raising HDL-C will translate into benefit [18].

These findings support the concept that HDL-C is more a marker of metabolic context than a direct causal protective factor. The protective properties of HDL may relate more to functional measures such as macrophage cholesterol efflux capacity (CEC). In a study of HDL function and atherosclerosis, CEC was inversely associated with carotid intima–media thickness and coronary disease status independent of HDL-C level [19]. Saturated fats may increase HDL-C without necessarily improving HDL functionality. Therefore, HDL-C increases with coconut oil do not “cancel out” LDL-related risk [10-12,18,19].

Deconstructing Endocrine and Metabolic Claims

Beyond lipidology, coconut oil is frequently promoted for its effects on weight loss, thyroid function, and testosterone levels. Peer-reviewed research, however, indicates that many of these claims are based on mechanistic overreach, conflation with purified MCT preparations, or misinterpretations of pharmacologic studies.

Weight Loss and Adiposity

The claim that coconut oil aids in weight loss is frequently derived from studies of purified MCT oils enriched in C8:0 and C10:0, which can increase postprandial thermogenesis and satiety relative to long-chain fats in some settings [4]. However, systematic reviews and meta-analyses of trials specifically evaluating coconut oil show no clinically meaningful reductions in body weight, BMI, or waist circumference compared with other dietary fats, with findings often heterogeneous and sensitive to study design and whether coconut oil replaces (versus adds to) other calories [20,21].

A major factor is the “calorie displacement” issue: if coconut oil is added on top of baseline intake rather than substituted isocalorically for other fats, total energy intake increases and any small thermogenic differences become clinically negligible [20]. Additionally, coconut oil’s dominance of C12:0 and C14:0 differentiates it from purified MCT oils, making large extrapolations from C8:0/C10:0 studies biologically tenuous [1,4,5].

The Thyroid–Butyrate Fallacy

A recurrent claim in non-scholarly sources is that coconut oil contains butyric acid and that this allegedly improves thyroid function by increasing T3 uptake in glial cells. This claim is inaccurate on composition and mechanism:

Chemical composition: Coconut oil contains negligible butyric acid (C4:0); butirato is primarily associated with ruminant milk fat and with microbial fermentation of dietary fibra in the colon [2,3].
Mechanistic confusion: The “butyrate/T3 uptake” narrative appears to conflate dietary butyrate with sodium phenylbutyrate, a pharmacologic chemical chaperone. Sodium phenylbutyrate has been studied in cellular models of monocarboxylate transporter 8 (MCT8) deficiency for its ability to rescue thyroid hormone transport defects [22]. There is no clinical evidence that consuming coconut oil (which lacks meaningful butyrate) improves thyroid hormone transport or T3 uptake in the brain.

Testosterone and Dietary Fat

The relationship between dietary fat and testosterone is often cited as a reason to consume high amounts of saturated fat. While very low-fat diets can modestly reduce testosterone in some intervention studies, this does not establish a requirement for high saturated fat intake. A systematic review and metaanálisis comparing low-fat versus higher-fat diets in men found lower testosterone on low-fat diets, though study sizes were small and levels often remained within reference ranges [23].

In clinical practice, excess adiposity is a dominant, modifiable driver of low testosterone in men via multiple pathways, including changes in sex hormone–binding globulin and increased aromatization in adipose tissue. Meta-analytic data show that weight loss—especially with larger magnitude loss—can significantly increase testosterone concentrations, with the degree of weight loss predicting the rise in testosterone [24,25]. Therefore, for men concerned about testosterone, sustainable weight loss and cardiometabolic risk reduction are typically more impactful than increasing saturated fat intake, which may worsen atherogenic lipoprotein exposure [9-12,24,25].

Antimicrobial and Antiviral Potential: Lab vs. Life

The antimicrobial and antiviral claims for coconut oil often cite lauric acid and monolaurin effects on lipid-coated pathogens in vitro. While these mechanisms are biologically plausible and robust in laboratory settings, translation through dietary intake to meaningful systemic infection prevention in humans remains uncertain. Clinical studies have explored virgin coconut oil (VCO) as adjunct therapy in COVID-19, reporting improvements in inflammatory markers such as C-reactive protein (CRP) and symptom timelines in small trials [26,27]. However, these studies are limited by sample size, setting, and adjunctive-care context; larger, well-controlled trials would be necessary before positioning VCO as an evidence-based systemic antimicrobial strategy [26,27]. Many traditional and supported uses of coconut-derived lipids remain topical (e.g., skin barrier and dermatologic applications) rather than systemic disease prevention.

De Novo Lipogenesis: The Physiological Redundancy of SFA

A central question in the discussion of saturated fat is whether the human body requires dietary intake of saturated fatty acids. From a physiological standpoint, saturated fatty acids are not essential nutrients because the human body can synthesize saturated and monounsaturated fats de novo. De novo lipogenesis (DNL) occurs primarily in liver and adipose tissue, converting excess carbohydrate substrates into fatty acids, with palmitate (C16:0) a major end-product that can be stored, oxidized, elongated, or desaturated for structural and signaling needs [28,29].

Research in human adipocyte models demonstrates that preadipocytes can differentiate and accumulate triacylglycerol even in the complete absence of exogenous fat, with DNL providing saturated fatty acids (including 12:0 through 18:0) and, via desaturation, monounsaturated fatty acids required for normal lipid droplet formation and cellular maturation [30]. In humans, higher-carbohydrate feeding can markedly increase DNL flux under specific metabolic conditions, underscoring that endogenous fatty acid synthesis can maintain saturated fat pools even when dietary saturated fat intake is low [28,31].

Because the body can synthesize saturated fat, there is no established minimum dietary requirement for saturated fatty acids. This contrasts with essential fatty acids (e.g., linoleic acid and alpha-linolenic acid), which humans cannot synthesize and must obtain from the diet [32].

All-Cause Mortality and the Replacement Paradigm

The impact of dietary fat on longevity is a critical endpoint in nutritional science. While cardiovascular-specific outcomes are central, evidence on all-cause mortality further supports that fat “quality” and substitution patterns matter.

Evidence from Large-Scale Cohort Studies

In the NIH-AARP Diet and Health Study (over 521,000 participants followed for 16 years), higher saturated fat intake was associated with higher total mortality, whereas isocaloric replacement of saturated fat with grasas insaturadas was associated with lower mortality risk [33]. Other large prospective cohorts similarly report divergent associations of dietary fat types with mortality, supporting the replacement of saturated and trans fats with unsaturated fats [34]. (As with all observational evidence, residual confusor is possible; nonetheless, consistency with lipid-mediated mechanisms strengthens plausibility.)

Contradictory Findings in Recent Meta-Analyses

Systematic reviews of RCTs have sometimes found limited effects of saturated-fat reduction on all-cause mortality, particularly when follow-up is short and when the replacement nutrient is not specified. However, RCT evidence more consistently shows reductions in composite cardiovascular events when saturated fats are reduced and replaced with polyunsaturated fats, rather than with refined carbohydrate [9,35]. These patterns reinforce that “replacement specificity” is not an academic nuance but a determinant of measurable benefit.

Global Health Guidelines and the Misinformation Surge

Global health authorities remain consistent that saturated fat should be limited and that replacement with unsaturated fats is preferred. The World Health Organization recommends limiting saturated fat intake and emphasizes replacing saturated fats with unsaturated fats as part of a healthy diet pattern [32]. The American Heart Association similarly recommends replacing saturated fats with polyunsaturated and monounsaturated fats to reduce cardiovascular risk [9].

Summary of Major Health Guidelines

Organization | Saturated Fat Recommendation | Primary Goal

WHO | Limit saturated fat; replace with unsaturated fats [32] | Prevention of non-communicable diseases
AHA | Emphasize replacement of saturated fat with unsaturated fats [9] | Reduction of ASCVD risk

The persistence of pro–coconut oil narratives is facilitated by confusion between surrogate markers (e.g., HDL-C) and causal pathways and clinical endpoints (e.g., apoB particle exposure, myocardial infarction, derrame cerebral). While short-term studies may show favorable changes in selected biomarkers, the best-supported lipid-causal framework and RCT/meta-analytic evidence indicate that coconut oil raises LDL-C relative to unsaturated vegetable oils, which is not aligned with a heart-healthy replacement strategy [6-12].

Conclusion

The comprehensive analysis of peer-reviewed research regarding coconut oil and saturated fat reveals a significant gap between public perception and scientific reality. Coconut oil is a concentrated source of saturated fatty acids that increases LDL-C compared with non-tropical unsaturated oils in randomized trials and meta-analyses, and LDL-related apoB particle exposure is causal in ASCVD [6,7,10-13]. The parallel increase in HDL-C does not establish cardiovascular protection, given failed HDL-raising trials and Mendelian randomization evidence indicating that raising HDL-C is not necessarily causal for lowering myocardial infarction risk [14-18].

Furthermore, the purported benefits of coconut oil for weight loss, thyroid function, and endocrine optimization are either weakly supported, inconsistent in human trials, or based on conflation with different compounds or purified MCT preparations [20-23]. Finally, the body’s capacity for de novo lipogenesis renders dietary saturated fat physiologically non-essential; essential fatty acids are instead obtained from unsaturated fat sources [28-32]. For individuals seeking to optimize cardiovascular health and overall longevity, the evidence supports replacing saturated fats, including coconut oil, with plant-based unsaturated oils shown to improve perfiles lipídicos and reduce cardiovascular event risk within broader healthy dietary patterns [9-12,33-35].

Referencias

1. Newport MT, Dayrit FM. Analysis of 26 Studies of the Impact of Coconut Oil on Lipid Parameters: Beyond Total and LDL Cholesterol. Nutrients. 2025;17(3):514. Published 2025 Jan 30. doi:10.3390/nu17030514
2. Bezard J, Bugaut M, Clement G. Triglyceride composition of coconut oil. J Am Oil Chem Soc. 1971;48(3):134-139. doi:10.1007/BF02545736.
3. Marina AM, Man YB, Nazimah SA, Amin I. Antioxidant capacity and phenolic acids of virgin coconut oil. Int J Food Sci Nutr. 2009;60 Suppl 2:114-123. doi:10.1080/09637480802549127
4. Bach AC, Babayan VK. Medium-chain triglycerides: an update. Am J Clin Nutr. 1982;36(5):950-962. doi:10.1093/ajcn/36.5.950
5. Swift LL, Hill JO, Peters JC, Greene HL. Medium-chain fatty acids: evidence for incorporation into chylomicron triglycerides in humans. Am J Clin Nutr. 1990;52(5):834-836. doi:10.1093/ajcn/52.5.834
6. Neelakantan N, Seah JYH, van Dam RM. The Effect of Coconut Oil Consumption on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Clinical Trials. Circulation. 2020;141(10):803-814. doi:10.1161/CIRCULATIONAHA.119.043052
7. Duarte AC, Spiazzi BF, Zingano CP, et al. The effects of coconut oil on the cardiometabolic profile: a systematic review and meta-analysis of randomized clinical trials. Lipids Health Dis. 2022;21(1):83. Published 2022 Aug 31. doi:10.1186/s12944-022-01685-z
8. Khaw KT, Sharp SJ, Finikarides L, et al. Randomised trial of coconut oil, olive oil or butter on blood lipids and other cardiovascular risk factors in healthy men and women. BMJ Open. 2018;8(3):e020167. Published 2018 Mar 6. doi:10.1136/bmjopen-2017-020167
9. Sacks FM, Lichtenstein AH, Wu JHY, et al. Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association. Circulation. 2017;136(3):e1-e23. doi:10.1161/CIR.0000000000000510
10. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144
11. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681. doi:10.1016/S0140-6736(10)61350-5
12. Sehayek D, Cole J, Björnson E, et al. ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk. J Clin Lipidol. 2025;19(4):844-859. doi:10.1016/j.jacl.2025.05.024
13. Ference BA, Kastelein JJP, Catapano AL. Lipids and Lipoproteins in 2020. JAMA. 2020;324(6):595-596. doi:10.1001/jama.2020.5685
14. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089-2099. doi:10.1056/NEJMoa1206797
15. Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med. 2017;376(20):1933-1942. doi:10.1056/NEJMoa1609581
16. AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-2267. doi:10.1056/NEJMoa1107579
17. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203-212. doi:10.1056/NEJMoa1300955
18. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572-580. doi:10.1016/S0140-6736(12)60312-2
19. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127-135. doi:10.1056/NEJMoa1001689
20. Swarnamali H, Ranasinghe P, Hills AP, Jayawardena R. Coconut oil consumption and bodyweight reduction: a systematic review and meta-analysis. Minerva Endocrinol (Torino). 2023;48(1):76-87. doi:10.23736/S2724-6507.21.03654-X
21. Gaeini Z, Bahadoran Z, Malmir H, Mirmiran P. Dose-dependent effect of coconut oil supplementation on obesity indices: a systematic review and dose-response meta-analysis of clinical trials. BMC Nutr. 2025;11(1):113. Published 2025 Jun 6. doi:10.1186/s40795-025-01090-6
22. Braun D, Bohleber S, Vatine GD, Svendsen CN, Schweizer U. Sodium Phenylbutyrate Rescues Thyroid Hormone Transport in Brain Endothelial-Like Cells. Thyroid. 2022;32(7):860-870. doi:10.1089/thy.2021.0643
23. Whittaker J, Wu K. Low-fat diets and testosterone in men: Systematic review and meta-analysis of intervention studies. J Steroid Biochem Mol Biol. 2021;210:105878. doi:10.1016/j.jsbmb.2021.105878
24. Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168(6):829-843. Published 2013 May 2. doi:10.1530/EJE-12-0955
25. Muir CA, Wittert GA, Handelsman DJ. Approach to the Patient: Low Testosterone Concentrations in Men With Obesity. J Clin Endocrinol Metab. 2025;110(9):e3125-e3130. doi:10.1210/clinem/dgaf137
26. Angeles-Agdeppa I, Nacis JS, Capanzana MV, Dayrit FM, Tanda KV. Virgin coconut oil is effective in lowering C-reactive protein levels among suspect and probable cases of COVID-19. J Funct Foods. 2021;83:104557. doi:10.1016/j.jff.2021.104557
27. Angeles-Agdeppa I, Nacis JS, Dayrit FM, Tanda KV. Virgin coconut oil (VCO) supplementation relieves symptoms and inflammation among COVID-19 positive adults: a single-blind randomized trial. J Nutr Sci. 2024;13:e5. Published 2024 Jan 23. doi:10.1017/jns.2023.118
28. Hellerstein MK. De novo lipogenesis in humans: metabolic and regulatory aspects. Eur J Clin Nutr. 1999;53 Suppl 1:S53-S65. doi:10.1038/sj.ejcn.1600744
29. Softic S, Cohen DE, Kahn CR. Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease. Dig Dis Sci. 2016;61(5):1282-1293. doi:10.1007/s10620-016-4054-0
30. Collins JM, Neville MJ, Pinnick KE, et al. De novo lipogenesis in the differentiating human adipocyte can provide all fatty acids necessary for maturation. J Lipid Res. 2011;52(9):1683-1692. doi:10.1194/jlr.M012195
31. Hudgins LC, Hellerstein MK, Seidman CE, Neese RA, Tremaroli JD, Hirsch J. Relationship between carbohydrate-induced hypertriglyceridemia and fatty acid synthesis in lean and obese subjects. J Lipid Res. 2000;41(4):595-604.
32. World Health Organization. Healthy diet. Fact sheet. 26 Jan 2026.
33. Zhuang P, Zhang Y, He W, et al. Dietary Fats in Relation to Total and Cause-Specific Mortality in a Prospective Cohort of 521 120 Individuals With 16 Years of Follow-Up. Circ Res. 2019;124(5):757-768. doi:10.1161/CIRCRESAHA.118.314038
34. Wang DD, Li Y, Chiuve SE, et al. Association of Specific Dietary Fats With Total and Cause-Specific Mortality. JAMA Intern Med. 2016;176(8):1134-1145. doi:10.1001/jamainternmed.2016.2417
35. Hooper L, Martin N, Abdelhamid A, Davey Smith G. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev. 2015;(6):CD011737. Published 2015 Jun 10. doi:10.1002/14651858.CD011737